Streptavidin suppresses T cell activation and inhibits IL-2 production and CD25 expression

Cytokine

Volumn 58, Issue 3, 2012, Pages 431-436

  Yomogida, Kentaro ^a,b   Chou, Yuan ^a,b   Pang, Jonathan ^c   Baravati, Bobby ^c   Maniaci, Brian J ^c   Wu, Shili ^c   Zhu, Yong ^c   Chu, Cong Qiu ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c VivoScript Inc   (United States)

Author keywords

Biotin; Interleukin 2; Interleukin 2 receptor; Streptavidin; T Cell activation

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY TEST; DRUG CONJUGATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE ACTIVATION;

CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; REAL-TIME POLYMERASE CHAIN REACTION; STREPTAVIDIN; T-LYMPHOCYTES;

EID: 84862806936     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.02.007     Document Type: Article

References (46)

1. Tausig F., Wolf F.J. Streptavidin - a substance with avidin-like properties produced by microorganisms. Biochem Biophys Res Commun 1964, 14:205-209.
2. Gitlin G., Khait I., Bayer E.A., Wilchek M., Muszkat K.A. Studies on the biotin-binding sites of avidin and streptavidin. A chemically induced dynamic nuclear polarization investigation of the status of tyrosine residues. Biochem J 1989, 259:493-498.
3. Forero A., Weiden P.L., Vose J.M., Knox S.J., LoBuglio A.F., Hankins J., et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004, 104:227-236.
4. Kalofonos H.P., Rusckowski M., Siebecker D.A., Sivolapenko G.B., Snook D., Lavender J.P., et al. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med 1990, 31:1791-1796.
5. Shen S., Forero A., LoBuglio A.F., Breitz H., Khazaeli M.B., Fisher D.R., et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 2005, 46:642-651.
6. Lazzeri E., Pauwels E.K., Erba P.A., Volterrani D., Manca M., Bodei L., et al. Clinical feasibility of two-step streptavidin/111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis. Eur J Nucl Med Mol Imaging 2004, 31:1505-1511.
7. Fawwaz R.A., Oluwole O.O., DePaz H.A., Jin M.X., Wang T.S., Hardy M.A., et al. Peritransplant streptavidin recipient treatment prolongs rat cardiac allograft survival. Transplantation 2002, 73:1954-1956.
8. Witkowski P., Fawwaz R.A., Jin M.X., DePaz H.A., Oluwole O.O., Hardy M.A., et al. Effect of streptavidin on cardiac allograft prolongation is due to host T-cell suppression. Transplant Proc 2005, 37:116-118.
9. Cornell L.D., Smith R.N., Colvin R.B. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008, 3:189-220.
10. Felix N.J., Allen P.M. Specificity of T-cell alloreactivity. Nat Rev Immunol 2007, 7:942-953.
11. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med 2001, 345:340-350.
12. Goodnow C.C., Sprent J., Fazekas de St Groth B., Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
13. Pascual M., Theruvath T., Kawai T., Tolkoff-Rubin N., Cosimi A.B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002, 346:580-590.
14. Meier J., Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011, 17:3204-3212.
15. Yoon K.H. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol 2010, 2010:686480.
16. Svensson A., Chambers C., Ganemo A., Mitchell S.A. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin 2011, 27:1395-1406.
17. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009, 60:643-659.
18. Kim H.P., Imbert J., Leonard W.J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006, 17:349-366.
19. Hemenway C.S., Heitman J. Calcineurin. Structure, function, and inhibition. Cell Biochem Biophys 1999, 30:115-151.
20. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226:544-547.
21. Siekierka J.J., Staruch M.J., Hung S.H., Sigal N.H. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol 1989, 143:1580-1583.
22. Powell J.D., Delgoffe G.M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010, 33:301-311.
23. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
24. Bergan S., Rugstad H.E., Bentdal O., Sodal G., Hartmann A., Leivestad T., et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation 1998, 66:334-339.
25. Nielsen O.H., Vainer B., Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001, 15:1699-1708.
26. Weimer R., Deisz S., Dietrich H., Renner F., Bodeker R.H., Daniel V., et al. Impact of maintenance immunosuppressive regimens - balance between graft protective suppression of immune functions and a near physiological immune response. Transpl Int 2011, 24:596-609.
27. Peipp M., Kupers H., Saul D., Schlierf B., Greil J., Zunino S.J., et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 2002, 62:2848-2855.
28. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384.
29. Sancho D., Gomez M., Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005, 26:136-140.
30. Zola H. Markers of cell lineage, differentiation and activation. J Biol Regul Homeost Agents 2000, 14:218-219.
31. Hargreaves R.G., Borthwick N.J., Gilardini Montani M.S., Piccolella E., Carmichael P., Lechler R.I., et al. Induction of apoptosis following antigen presentation by T cells: anergy and apoptosis are two separate phenomena. Transplant Proc 1997, 29:1102-1104.
32. Mock D.M. Marginal biotin deficiency is teratogenic in mice and perhaps humans: a review of biotin deficiency during human pregnancy and effects of biotin deficiency on gene expression and enzyme activities in mouse dam and fetus. J Nutr Biochem 2005, 16:435-437.
33. Gehrig K.A., Dinulos J.G. Acrodermatitis due to nutritional deficiency. Curr Opin Pediatr 2010, 22:107-112.
34. McMahon R.J. Biotin in metabolism and molecular biology. Annu Rev Nutr 2002, 22:221-239.
35. Bonilla F.A., Kokron C.M., Swinton P., Geha R.S. Targeted gene disruption of murine CD7. Int Immunol 1997, 9:1875-1883.
36. Lazarovits A.I., Rochon J., Banks L., Hollomby D.J., Muirhead N., Jevnikar A.M., et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 1993, 150:5163-5174.
37. Frankel A.E., Laver J.H., Willingham M.C., Burns L.J., Kersey J.H., Vallera D.A. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma 1997, 26:287-298.
38. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
39. Rodriguez-Melendez R., Lewis B., McMahon R.J., Zempleni J. Diaminobiotin and desthiobiotin have biotin-like activities in Jurkat cells. J Nutr 2003, 133:1259-1264.
40. Rodriguez-Melendez R., Camporeale G., Griffin J.B., Zempleni J. Interleukin-2 receptor-gamma-dependent endocytosis depends on biotin in Jurkat cells. Am J Physiol Cell Physiol 2003, 284:C415-C421.
41. Zempleni J. Uptake, localization, and noncarboxylase roles of biotin. Annu Rev Nutr 2005, 25:175-196.
42. Stanley J.S., Griffin J.B., Zempleni J. Biotinylation of histones in human cells. Effects of cell proliferation. Eur J Biochem 2001, 268:5424-5429.
43. Hassan Y.I., Zempleni J. Epigenetic regulation of chromatin structure and gene function by biotin. J Nutr 2006, 136:1763-1765.
44. Kuroishi T., Rios-Avila L., Pestinger V., Wijeratne S.S., Zempleni J. Biotinylation is a natural, albeit rare, modification of human histones. Mol Genet Metab 2011, 104:537-545.
45. Rodriguez-Melendez R., Schwab L.D., Zempleni J. Jurkat cells respond to biotin deficiency with increased nuclear translocation of NF-kappaB, mediating cell survival. Int J Vitam Nutr Res 2004, 74:209-216.
46. Griffin J.B., Rodriguez-Melendez R., Zempleni J. The nuclear abundance of transcription factors Sp1 and Sp3 depends on biotin in Jurkat cells. J Nutr 2003, 133:3409-3415.